Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome(IBS-D)

美沙拉嗪治疗腹泻型肠易激综合征（IBS-D）的疗效和作用方式

• 批准号: MC_G1002464
• 负责人: Robin Spiller
• 金额: $ 92.23万
• 依托单位: University of Nottingham
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2010
• 资助国家: 英国
• 起止时间: 2010 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MC_G1002464
• 关键词: Efficacy; mode; action; mesalazine; treatment

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

目前GtR中并没有所有资助研究的摘要。这通常是因为在提交提案时不需要摘要，但也可能是因为摘要中包含个人详细信息等敏感信息。

项目成果

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.

美沙拉嗪治疗腹泻型肠易激综合征 (IBS-D) 的功效和作用方式：随机对照试验的研究方案。

• DOI: 10.1186/1745-6215-14-10
• 发表时间: 2013
• 期刊: Trials
• 影响因子: 2.5
• 作者: Leighton MP

Increased fasting small-bowel water content in untreated coeliac disease and scleroderma as assessed by magnetic resonance imaging.

通过磁共振成像评估，未经治疗的乳糜泻和硬皮病的空腹小肠水含量增加。

• DOI: 10.1177/2050640619860372
• 发表时间: 2019
• 期刊: United European gastroenterology journal
• 影响因子: 6
• 作者: Lam C

A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).

• DOI: 10.1136/gutjnl-2015-309122
• 发表时间: 2016-01
• 期刊: Gut
• 影响因子: 24.5
• 作者: Lam C;Tan W;Leighton M;Hastings M;Lingaya M;Falcone Y;Zhou X;Xu L;Whorwell P;Walls AF;Zaitoun A;Montgomery A;Spiller R
• 通讯作者: Spiller R

Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders.

• DOI: 10.1038/s41588-021-00950-8
• 发表时间: 2021-11
• 期刊: Nature genetics
• 影响因子: 30.8
• 作者: Eijsbouts C;Zheng T;Kennedy NA;Bonfiglio F;Anderson CA;Moutsianas L;Holliday J;Shi J;Shringarpure S;23andMe Research Team;Voda AI;Bellygenes Initiative;Farrugia G;Franke A;Hübenthal M;Abecasis G;Zawistowski M;Skogholt AH;Ness-Jensen E;Hveem K;Esko T;Teder-Laving M;Zhernakova A;Camilleri M;Boeckxstaens G;Whorwell PJ;Spiller R;McVean G;D'Amato M;Jostins L;Parkes M
• 通讯作者: Parkes M

The shifting interface between IBS and IBD.

IBS 和 IBD 之间的转换界面。

• DOI: 10.1016/j.coph.2011.09.009
• 发表时间: 2011
• 期刊: Current opinion in pharmacology
• 影响因子: 4
• 作者: Spiller R